Rhokiinsa (netarsudil)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- netarsudil
- Company
- Santen Oy
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle; Ocular Hypertension
- CHMP opinion
- Thu 19 Sep 2019
- EU approval
- Tue 19 Nov 2019
- Designations
- Additional monitoring
- Application
- EMEA/H/C/004583
- ATC
- S01EX05
- Official record
- www.ema.europa.eu
Indication
Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Roclanda Authorised · Santen Oy
Follow Rhokiinsa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.